Dr. Saurabh Rajguru, MD

Dr. Rajguru practices at University Health Services - Madison (Highland Ave) in Madison, Wisconsin.

Dr. Rajguru's NPI, 1104056597, was assigned on July 20, 2009. Dr. Rajguru graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 2009. Dr. Rajguru holds Wisconsin license 55384.

Dr. Rajguru's primary practice is University Health Services - Madison (Highland Ave), at 600 Highland Ave, Madison, WI 53792. The practice phone is (608) 265-1978.

Dr. Rajguru's primary practice is University Health Services - Madison (Highland Ave) in Madison, Wisconsin. Dr. Rajguru is also affiliated with University Hospital. The medical group on file is UW Health. Dmand AI also links Dr. Rajguru to 3 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account. Dr. Rajguru's employer is on file too: a school & student health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rajguru practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rajguru's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rajguru is board certified in hematology by the American Board of Internal Medicine. Dr. Rajguru is licensed in Wisconsin.

CMS data shows 1,314 Medicare services from Dr. Rajguru across 13 procedure codes in 2024, for 315 Medicare patients. Medicare paid $52,539 for them.

CMS counts 315 Medicare patients who saw Dr. Rajguru in 2024. The largest group is 65 to 74, with 131 patients. 70% of them have high blood pressure, and 68% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rajguru's median patient age at 73, with 45% women.

In 2024, Dr. Rajguru wrote 766 Medicare Part D claims for 101 patients. 88% of them were for generic drugs. CMS names the drug for 681 of them, across 17 drugs with 11 or more claims each, at $1,022,389 in total drug cost. In 2023, CMS named 620 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Rajguru for performance year 2024, reported as part of a group. Dr. Rajguru accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rajguru as offering telehealth.

Dmand AI links 17 papers to Dr. Rajguru, published from 2013 to 2024. 2014 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Mantle-Cell and Bendamustine Hydrochloride. Dr. Rajguru has published most often in J Natl Compr Canc Netw. Dr. Rajguru's most frequent co-authors are Reem Md Karmali, MD, Daniel J. Landsburg, MD and Weiyun Z. Ai, MD.

Dmand AI links Dr. Rajguru to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Waldenstrom Macroglobulinemia and Lymphoma, B-Cell. Loxo Oncology, Inc. sponsors the most, 2.

CMS Open Payments shows 6 general payments to Dr. Rajguru from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Taiho Oncology, Inc. paid the most, $44.

Dr. Rajguru graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 2009.